جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

3 مُخرَج نتائج البحث عن «SOX2»

مقالوصول مفتوح202410استشهاد· Semantic Scholar

Dexamethasone–tamoxifen combination exerts synergistic therapeutic effects in tamoxifen-resistance breast cancer cells

Bioscience Reports · مجلد 44 (7)

Tamoxifen (TAM) is a key player in estrogen receptor-positive (ER+) breast cancer (BC); however, ∼30% of patients experience relapse and a lower survival rate due to TAM resistance. TAM resistance was related to the over expression of SOX-2 gene, which is regulated by the E2F3 transcription factor in the Wnt signaling pathway. It was suggested that SOX-2 overexpression was suppressed by dexamethasone (DEX), a glucocorticoid commonly prescribed to BC patients. The aim of the present study is to explore the effect of combining DEX and TAM on the inhibition of TAM-resistant LCC-2 cells (TAMR-1) through modulating the E2F3/SOX-2-mediated Wnt signaling pathway. The effect of the combination therapy on MCF-7 and TAMR-1 cell viability was assessed. Drug interactions were analyzed using CompuSyn and SynergyFinder softwares. Cell cycle distribution, apoptotic protein expression, gene expression levels of SOX-2 and E2F3, and cell migration were also assessed. Combining DEX with TAM led to synergistic inhibition of TAMR-1 cell proliferation and migration, induced apoptosis, reduced SOX-2 and E2F3 expression and was also associated with S and G2-M phase arrest. Therefore, combining DEX with TAM may present an effective therapeutic option to overcome TAM resistance, by targeting the E2F3/SOX-2/Wnt signaling pathway, in addition to its anti-inflammatory effect.

dexamethasonetamoxifentamoxifen resistanceestrogen receptor-positive breast cancer
مقالوصول مغلق20221استشهاد· Semantic Scholar

Possible cytotoxic effect of allantoin on oral squamous cell carcinoma stemness (in vivo and in vitro model

The FASEB Journal · مجلد 36 (S1)

Cancer stem cells (CSCs) and associated tumor microenvironment (TM) have been proposed to mediate cancer progression, and therapeutic resistance rendering them valuable therapeutic targets in head and neck squamous cell carcinomas (HNSCC). Oral CSCs drive their tumorigenic effect via stromal fibroblasts. Phytochemicals like allantoin are extensively used in wound healing modulating fibroblast activity. The present study aimed to evaluate whether allantoin can modulate CSCs and/or TM and subsequently contribute to sensitization of cancer cells to chemotherapeutic agents. Hep2, OECs, DPSC cell lines were used to test the cytotoxicity of allantoin on cancer, oral epithelial cells, and normal dental pulp stem cells, respectively. The effect of allantoin and/or 5‐fluorouracil (5FU) on cell cycle, apoptosis and expression of stem cell and apoptotic markers was tested in vitro. Further validation was performed using in vivo 4‐nitroquinoline 1‐oxide model of tongue squamous cell carcinoma model with assessment of cytotoxic effect of allantoin by flow cytometry, immunohistochemical staining, western‐blot and RT‐PCR. Allantoin was safe on both normal oral epithelial cells and dental pulp stem cells. Allantoin showed a statistically significant and dose dependent increase in 5FU apoptotic effect via reduction of cancer stem cell markers CD133 and CD44. Regarding cell cycle arrest, there was no statistically significant difference with addition of allantoin to 5FU. In vivo, allantoin down‐regulated SOX2, NANOG, ALDH and OCT4 gene expression in tongue squamous cell carcinoma. Additionally, allantoin reduced the expression IL‐6, TGF‐Β, PDGF, α‐ SMA and CD163. Our results proposed that high concentration of allantoin drives its antitumorigenic effect. This was mediated by modulating stromal component of TM via down‐regulation of trans‐differentiation of cancer associated fibroblasts and tumor associated macrophages. These findings shed the light on potential use of allantoin as cytotoxic drug either alone or combined with other chemotherapeutic drugs.

allantoinoral squamous cell carcinomacancer stem cellstumor microenvironment